SCHEMBL6786403

SCHEMBL6786403

COC(=O)c1cc(OC)c(OC)cc1NC(=O)/C=C(/C)c1ccc(Cl)c(Br)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.50
KMT2A Q03164 3/20 0.50
ALDH1A1 P00352 11/20 0.49
HPGD P15428 7/20 0.49
POLB P06746 1/20 0.49
HSD17B10 Q99714 4/20 0.47
MAPK1 P28482 1/20 0.47
MEN1 O00255 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
LMNA P02545 1/20 0.45
GAA P10253 4/20 0.45
HTT P42858 1/20 0.45
MAPT P10636 1/20 0.45
GLA P06280 2/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
LTB4R Q15722 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6790898 0.92 KDM4E (0.50) KDM4EKMT2AALDH1A1HPGDPOLB
SCHEMBL6785190 0.92 KDM4E (0.51) KDM4EKMT2AALDH1A1HPGDHSD17B10
SCHEMBL6787614 0.90 KDM4E (0.53) KDM4EKMT2AALDH1A1HPGDPOLB
SCHEMBL6786762 0.90 KDM4E (0.53) KDM4EKMT2AALDH1A1HPGDPOLB
SCHEMBL6785403 0.85 TERT (0.53) KDM4EKMT2AALDH1A1HPGDPOLB
SCHEMBL6792144 0.83 MAPT (0.49) KDM4EKMT2AALDH1A1HPGDHSD17B10
SCHEMBL6785982 0.83 ALDH1A1 (0.46) KDM4EKMT2AALDH1A1HPGDPOLB
SCHEMBL6783723 0.83 KDM4E (0.46) KDM4EKMT2AALDH1A1HPGDPOLB
SCHEMBL6791397 0.81 MAPT (0.52) KDM4EKMT2AALDH1A1HPGDHSD17B10
SCHEMBL4028323 0.81 KDM4E (0.60) KDM4EKMT2AALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 KDM4E 1243/4885KMT2A 490/4885ALDH1A1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.